CNR1 antibody (Extracellular, N-Term)

Catalog No. ABIN7884842

The Rabbit Polyclonal anti-CNR1 antibody (ABIN7884842) specifically detects CNR1 in WB, IHC, IF, FACS, LCI and IC. The antibody is reactive with Human, Rat and Mouse samples.

Quick Overview for CNR1 antibody (Extracellular, N-Term) (ABIN7884842)

Target: CNR1 (Cannabinoid Receptor 1 (CNR1))

Reactivity: Human, Rat, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CNR1 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS), Live Cell Imaging (LCI), Immunochromatography (IC)

Grade: Carrier-free

Product Details anti-CNR1 Antibody

Binding Specificity: AA 84-99, Extracellular, N-Term

Purpose: A Rabbit Polyclonal Antibody to Cannabinoid Receptor 1

Predicted Reactivity: Human - identical, mouse - 15,16 amino acid residues identical

Purification: Affinity purified on immobilized antigen.

Immunogen: NKSLSSFKENEENIQC, corresponding to amino acid residues 84-99 of rat CB1 receptor

Isotype: IgG

Application Details

Application Notes:

WB: 1:200

FC: 2.5 μg per reaction

ICC: The optimal concentration should be determined by the user

IHC: 1:100

IP: The optimal concentration should be determined by the user

Comment:

Negative Control: (ABIN7235028)

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: 0.2 mL double distilled water (DDW)

Concentration: 1 mg/mL

Buffer: PBS pH 7.4

Preservative: Without preservative

Storage: -20 °C

Storage Comment: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C

Target Details for CNR1

Target: CNR1 (Cannabinoid Receptor 1 (CNR1))

Alternative Name: CB1

Background:

Synonyms: CB1, CB-R, CNR1, CB1R, CANN6, Brain-type cannabinoid receptor, Central cannabinoid receptor

Description: Cannabinoids have been used in Eastern medicine for many years as pain relievers.1 Δ9-tetrahydrocannabinol (THC), the major psychoactive compound in marijuana and hashish, has been shown to interact with two specific cannabinoid receptors: cannabinoid receptor 1 (CB1 receptor) and cannabinoid receptor 2 (CB2 receptor).2 The cannabinoid receptors can be distinguished by their amino acid sequences, signaling mechanisms, and tissue distributions.2 Both receptors belong to the G-protein coupled receptor (GPCR) superfamily. CB1 was shown to modulate several Ca2+ and K+ ion channels.2,3CB1 is primarily expressed in the central nervous system. However, expression of CB1 is also detected in the peripheral terminals, in non-neuronal peripheral tissues such as uterus, testes, spleen, as well as in cells of the immune system.3,4CB1 is implicated in many cellular functions such as neurotransmitter release, pain relief, cancer, and obesity.5,6 Growth inhibition of tumor cells was demonstrated following mixed CB1/CB2 agonist treatment in both prostate and non-melanoma skin cancers.5,6 Through their interaction with CB1, cannabinoid compounds stimulate appetite for sweets and palatable foods in particular, making CB1 an attractive therapeutic target for the treatment of obesity and eating disorders.7

Gene ID: 25248

UniProt: P20272

Pathways: Feeding Behaviour